Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
輝瑞、阿斯利康、賽諾菲和美因茲生物醫學將提升歐洲的製藥業水平
On Sunday, Pfizer (NYSE:PFE) and AstraZeneca Plc (NASDAQ:AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year's "Choose France" business summit. Together with the domestic Sanofi (NASDAQ:SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country.
週日，輝瑞（紐約證券交易所代碼：PFE）和阿斯利康集團（納斯達克股票代碼：AZN）等製藥公司宣佈，在今年的 “選擇法國” 商業峯會之前，他們將在法國的業務中總共投資近10億美元。阿斯利康將與國內賽諾菲（納斯達克股票代碼：SNY）、輝瑞、阿斯利康共同投資18.7億歐元，超過20億美元，用於擴大在該國的業務。
AstraZeneca committed 365 million euros, which is about $394 million, to enhance its facilities at its French manufacturing facility in Dunkirk. Pfizer pledged even more, making a commitment to invest 500 million euros or $540 million over the...
阿斯利康承諾提供3.65億歐元（約合3.94億美元），用於改善其位於...
登入免費觀看全文
登入/註冊